Possible targeting of G protein coupled receptors to manipulate inflammation in vivo using synthetic and natural ligands

Annals of the Rheumatic Diseases

Volumn 62, Issue SUPPL. 2, 2003, Pages 22-24

  Kinsel, J F ^a   Sitkovsky, M V ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE RECEPTOR BLOCKING AGENT; CAFFEINE; CYTOKINE; G PROTEIN COUPLED RECEPTOR; LIGAND; METHOTREXATE;

ANTIINFLAMMATORY ACTIVITY; CONFERENCE PAPER; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INFLAMMATION; INHIBITION KINETICS; LYMPHOID CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

EID: 0142156485     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.suppl_2.ii22     Document Type: Conference Paper

References (44)

1. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology (Huntingt) 2002;16:217-32.
2. McPherson JA, Barringhaus KG, Bishop GG, Sanders JM, Rieger JM, Hesselbacher SE, et al. Adenosine A2A receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model. Arterioscler Thromb Vasc Biol 2001;21:791-6.
3. Pockley AG. Heat shock proteins, inflammation, and cardiovascular disease. Circulation 2002;105:1012-17.
4. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002;300:729-35.
5. Mulvihill NT, Foley JB. Inflammation in acute coronary syndromes. Heart 2002;87:201-4.
6. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Ann Rev Pharmacol Toxicol 2001;41:775-87.
7. Van Belle H, Goossens F, Wynants J. Formation and release of purine catabolites during hypoperfusion, anoxia, and ischemia. Am J Pathol 1987;252:H886-93.
8. Winn HR, Rubio R, Curnish RR, Berne RM. Changes in regional cerebral blood flow (rCBF) caused by increase in CSF concentrations of adenosine and 2-chloroadenosine (CHL-ADO). J Cereb Blood Flow Metab 1981;1:401.
9. Rudolphi KA, Shubert P. Adenosine and brain ischemia In: Bellardinelli L, Pelleg A eds. Adenosine and adenine nucleotides: from molecular biology to integrative physiology. Norwell: Kluwer, 1995:391-7.
10. Cronstein BN. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994;76:5-13.
11. Firestein GS. Anti-inflammatory effects of adenosine kinase inhibitors in acute and chronic inflammation. Drug Dev Res 1996;39:371-6.
12. Eigler A, Greten TF, Sinha B, Haslberger C, Sullivan GW, Endres S. Endogenous adenosine curtails lipopolysaccharide-stimulated tumour necrosis factor synthesis. Scand J Immunol 1997;45:132-9.
13. Sullivan GW, Linden J. Role of A2A adenosine receptors in inflammation. Drug Dev Res 1998;45:103-12.
14. Huang S, Koshiba M, Apasov S, Sitkovsky M. Role of A2A adenosine receptor-mediated signaling in inhibition of T-cell activation and expansion. Blood 1997;90:1600-10.
15. Koshiba M, Kojima H, Huang S, Apasov S, Sitkovsky MV. Memory of extracellular adenosine/A2A purinergic receptor-mediated signalling in murine T-cells. J Biol Chem 1997;272:25881.
16. Ohta A, Sitkovsky M. Role of G protein-coupled adenosine receptors in down-regulation of inflammation and protection from tissue damage. Nature 2001;414:916-20.
17. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-52.
18. Fredholm BB, Arslan, G, Halldner L, Kull B, Schulte G, Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol 2000;362:364-74.
19. Libert F, Parmentier M, Lefort A, Dinsart C, Van Sande J, Maenhaut C, et al. Selective amplification and cloning of four new members of the G protein-coupled receptor family. Science 1989;244:569-72.
20. Olah ME, Stiles GL. Adenosine receptor subtypes: characterization and therapeutic regulation. Ann Rev Pharmacol Toxicol 1995;35:581-606.
21. Linden J, Thai T, Figler H, Robeva AS. Characterization of human A2B adenosine receptors: radioligand binding, Western blotting and coupling to G(q) in HEK-293 and HMC-1 mast cells. Mol Pharmacol 1999;56:705-13.
22. Jockers R, Linder ME, Hohenegger M, Nanoff C, Bertin B, Strosberg AD, et al. Species difference in the G protein selectivity of the human and bovine A1-adenosine receptor. J Biol Chem 1994;269:32077-84.
23. Akbar M, Okajima F, Tomura H, Shimegi S, Kondo Y. A single species of A1 adenosine receptor expressed in Chinese hamster ovary cells not only inhibits cAMP accumulation but also stimulates phospholipase C and arachidonate release. Mol Pharmacol 1994;45:1036-42.
24. Freund S, Ungerer M, Lohse MJ. A1 adenosine receptors expressed in CHO-cells couple to adenylyl cyclase and to phospholipase C. Naunyn Schmiedebergs Arch Pharmacol 1994;350:49-56.
25. Gerwins P, Fredholm BB. Activation of adenosine A1 and bradykinin receptors increases protein kinase C and phospholipase D activity in smooth muscle cells. Naunyn Schmiedebergs Arch Pharmacol 1995;351:186-93.
26. Palmer TM, Gettys TW, Stiles GL. Differential interaction with and regulation of multiple G-proteins by the rat A3 adenosine receptor. J Biol Chem 1995;270:16895-902.
27. Olah ME. Identification of A2B adenosine receptor domains involved in selective coupling to G s: analysis of chimeric A1/A2A adenosine receptors. J Biol Chem 1997;272:337-44.
28. Pierce KD, Furlong TJ, Selbie LA, Shine J. Molecular cloning and expression of an adenosine receptor from human brain. Biochem Biophys Res Commun 1992;187:86-93.
29. olf in rat striatum. Mol Pharmacol 2000;58:771-7.
30. Gao Z, Chen T, Weber MJ, Linden J. A2B adenosine and P2Y2 receptors stimulate mitogen-activated protein kinase in human embryonic kidney-293 cells: cross-talk between cyclic AMP and protein kinase C pathways. J Biol Chem 1999;274:5972-80.
31. Gomez G, Apasov S, Sitkovsky MV. Immunosuppressive effects of extracellular adenosine on immune cells: implications for the pathogenesis of ADA SCID and immunomodulation. Drug Dev Res 2001;53:218-24.
32. Parmely MJ, Zhou WW, Edwards ICK, Borcherding DR, Silverstein R, Morrison DC. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor- production and protect mice against endotoxin challenge. J Immunol 1993;151:389-96.
33. Boumo MG, Stad RK, Wildenberg FAJMvd, Buurman WA. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 1994;153:4159-68.
34. Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES. Adenosine receptor agonists differentially regulate IL-10, TNF-α and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 1996;157:4634-40.
35. Hasko G, Nemeth ZH, Vizi ES, Salzman AL, Szabo C. An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-production and prevents lethality in endotoxemic mice. Eur J Pharmacol 1998;358:261-8.
36. McWhinney CD, Dudley MW, Bowlin TL, Peet NP, Schook L, Bradshaw M, et al. Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor. Eur J Pharmacol 1996;310:209-16.
37. Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS. Inhibition of TNF-α expression by adenosine: role of A3 adenosine receptors. J Immunol 1996;156:3435-42.
38. Link AA, Kino T, Worth JA, McGuire JL, Crane ML, Chrousos GP, et al. Ligand-activation of the adenosine A2A receptors inhibits IL-12 production by human monocytes. J Immunol 2000;164:436-442.
39. Armstrong JM, Chen JF, Schwarzschild MA, Apasov S, Smith PT, Caldwell C, et al. Gene dose effect reveals no Gs protein-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A receptor gene-deficient mice. Biochem J 2001;354:123-30.
40. Montesinos MC, Gadangi P, Longaker M, Sung J, Levine J, Nilsen D, et al. Wound healing is accelerated by agonists of A2 (G alpha s-linked) receptors. J Exp Med 1997;186:1615-20.
41. Montesinos MC, Desai A, Chen JF, Yee H, Schwarzschild MA, Fink JS, et al. Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A2A receptors. Am J Pathol 2002;160:2009-18.
42. Montesinos MC, Yap JS, Desai A, Posadas I, McCrary CT, Cronstein BN. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonist theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum 2000;43:563-5.
43. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory disease. Arthritis Res 2002;44:266-73.
44. Gonzalez NJ, Isaacs LL. Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutrition and detoxification support. Nutrition and Cancer 1999;33:117-24.